2024
TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarrayArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantage
2023
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trialsDisparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatients
2019
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Mohler J, Antonarakis E, Armstrong A, D'Amico A, Davis B, Dorff T, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Ippolito J, Kane C, Kuettel M, Lang J, McKenney J, Netto G, Penson D, Plimack E, Pow-Sang J, Pugh T, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small E, Spratt D, Srinivas S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 479-505. PMID: 31085757, DOI: 10.6004/jnccn.2019.0023.Peer-Reviewed Original ResearchConceptsProstate cancerRisk stratificationNCCN Clinical Practice GuidelinesMultigene molecular testingSecondary hormonal therapyAndrogen deprivation therapySomatic genetic testingClinical practice guidelinesDeprivation therapyHormone therapyLocalized diseaseAdvanced diseaseNCCN GuidelinesTreated patientsTreatment optionsMolecular testingProstateGenetic testingCancerTherapyPractice guidelinesPatientsNCCNDiseaseGuidelines
2016
Prostate Cancer, Version 1.2016.
Mohler J, Armstrong A, Bahnson R, D'Amico A, Davis B, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Kane C, Kawachi M, Kuettel M, Lee R, Meeks J, Penson D, Plimack E, Pow-Sang J, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus T, Small E, Sonpavde G, Srinivas S, Strope S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 1.2016. Journal Of The National Comprehensive Cancer Network 2016, 14: 19-30. PMID: 26733552, DOI: 10.6004/jnccn.2016.0004.Peer-Reviewed Original ResearchConceptsProstate cancerMetastatic castration-recurrent prostate cancerCastration-recurrent prostate cancerTreatment of recurrent diseaseDiagnosis of prostate cancerRisk stratification methodsTreatment of menMetastatic diseaseRecurrent diseaseSystemic therapyNCCN GuidelinesHigh riskDiseaseDisease monitoringCancerNCCNManagement optionsStratification methodTreatmentRiskOptionsProstateTherapyGuidelinesDiagnosis